Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743795 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
NCT00743795 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 252 participants.
The verdict
NCT00743795, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1 chronic hepatitis C infection.
Interventions
- DRUG placebo
- DRUG Ribavirin
- DRUG GS-9190
- DRUG Peginterferon Alfa 2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743795
The ClinicalTrials.gov registry entry for NCT00743795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00743795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743795 about?
NCT00743795 is a clinical study titled "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection". The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1 chronic hepatitis C infection.
What is the current status of trial NCT00743795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2008-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00743795?
The interventions under investigation include: placebo (DRUG), Ribavirin (DRUG), GS-9190 (DRUG), Peginterferon Alfa 2a (DRUG).
Who is sponsoring clinical trial NCT00743795?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.